Approval · Notice of Compliance 36901 · 2026
RYMTI: Notice of Compliance 36901
Issued February 12, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36901
- Date
- February 12, 2026
- Company
- Lupin Pharma Canada LimitedLongueuil, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Changes to the manufacturing process
- Canadian reference product
- ENBREL
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RYMTI | Not yet assigned | — |
Medicinal ingredients
- ETANERCEPT 50 MG per ML
- ETANERCEPT 25 MG per 0.5ML
- ETANERCEPT 50 MG per PEN